XFOR
X4 Pharmaceuticals Inc

3,629
Mkt Cap
$386.47M
Volume
536,942.00
52W High
$26.83
52W Low
$1.35
PE Ratio
-0.44
XFOR Fundamentals
Price
$4.50
Prev Close
$4.42
Open
$4.43
50D MA
$3.65
Beta
1.53
Avg. Volume
531,320.11
EPS (Annual)
-$5.59
P/B
1.80
Rev/Employee
$17,881.12
Loading...
Loading...
News
all
press releases
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks·2d ago
News Placeholder
More News
News Placeholder
X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Acorn Capital Advisors LLC
Acorn Capital Advisors LLC lowered its stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) by 97.9% in the second quarter, according to the company in its most recent filing with...
MarketBeat·14d ago
News Placeholder
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of "Hold" from Brokerages
Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) have been given an average rating of "Hold" by the five ratings firms that are presently covering the stock, Marketbeat.com reports...
MarketBeat·15d ago
News Placeholder
X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Lowered by Zacks Research
Zacks Research lowered shares of X4 Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday...
MarketBeat·27d ago
News Placeholder
Wall Street Zen Upgrades X4 Pharmaceuticals (NASDAQ:XFOR) to "Hold"
Wall Street Zen raised shares of X4 Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·1mo ago
News Placeholder
MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
MeiraGTx (MGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +12.66% and -7.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Techne (TECH) Meets Q1 Earnings Estimates
Techne (TECH) delivered earnings and revenue surprises of 0.00% and -0.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock?
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial
The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said.
Stocktwits·3mo ago
<
1
2
...
>

Latest XFOR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.